| GlaxoSmithKline AG - Fluarix, Injektionssuspension | | 70042 | | 02 | | Fluarix | | Injektionssuspension | | J07BB02 | | Influenza, gereinigtes Antigen | | 13.08.2026 | | |
| | Zusammensetzung | | haemagglutininum influenzae A (H1N1) (Virus Stamm A/Missouri/11/2025 (H1N1)pdm09-like: reassortant virus IVR-278 derived from A/Switzerland/6849/2025) 15 µg, haemagglutininum influenzae A (H3N2) (Virus Stamm A/Darwin/1454/2025 (H3N2)-like: reassortant virus SAN-049A derived from A/Michigan/105/2025) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Tokyo/EIS13-175/2025-like: B/Tokyo/EIS13-175/2025, wild type (Victoria lineage)) 15 µg, polysorbatum 80 max. 415 µg, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.7 mg, kalium 0.1 mg, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. | | Packungsbestandteile | | | | Packungsnummer | Packungsgrösse | EFP | PP | Kat. | SL | In Refdata nicht gelistet |
|---|
| 003 | | | | B | | Nein | | 004 | 10 | | | B | | Nein |
|
|
